Invention Grant
- Patent Title: Compounds as LRRK2 kinase inhibitors
-
Application No.: US15114858Application Date: 2015-01-28
-
Publication No.: US10087186B2Publication Date: 2018-10-02
- Inventor: Xiao Ding , Luigi Piero Stasi , Zehong Wan , Colin Michael Edge
- Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
- Applicant Address: GB Brentford, Middlesex
- Assignee: GlaxoSmithKline Intellectual Property Development Limited
- Current Assignee: GlaxoSmithKline Intellectual Property Development Limited
- Current Assignee Address: GB Brentford, Middlesex
- Agent Nora L. Stein; Kathryn A. Lutomski
- Priority: WOPCT/CN2014/000139 20140129
- International Application: PCT/CN2015/000055 WO 20150128
- International Announcement: WO2015/113452 WO 20150806
- Main IPC: C07D487/04
- IPC: C07D487/04 ; A61K31/519
Abstract:
The present invention relates to novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).
Public/Granted literature
- US20170015668A1 COMPOUNDS Public/Granted day:2017-01-19
Information query
